A-412997, a selective dopamine D4 agonist, improves cognitive performance in rats

@article{Browman2005A412997AS,
  title={A-412997, a selective dopamine D4 agonist, improves cognitive performance in rats},
  author={Kaitlin E. Browman and Peter Curzon and Jia Bao Pan and Angela L Molesky and Victoria A. Komater and Michael W. Decker and Jorge D. Brioni and Robert B. Moreland and Gerard B. Fox},
  journal={Pharmacology Biochemistry and Behavior},
  year={2005},
  volume={82},
  pages={148-155}
}
The recent development of a highly selective dopamine D4 receptor agonist, A-412997 (2-(3',4',5',6'-tetrahydro-2'H-[2,4'] bipyridinyl-1'-yl)-N-m-tolyl-acetamide), has provided a pharmacological tool with which to conduct systematic investigations into the putative role for dopamine D4 receptors in the central nervous system. These present studies evaluated the potential cognitive enhancing properties of A-412997 in rat models of ADHD (5-trial repeated acquisition inhibitory avoidance in… Expand
Selective dopamine D4 receptor agonist (A-412997) improves cognitive performance and stimulates motor activity without influencing reward-related behaviour in rat
TLDR
Comparing the effects of a selective D4 receptor agonist, A-412997, with methylphenidate or amphetamine in preclinical models of efficacy versus abuse liability suggests that selective activation of the D4 receptors may represent a target for the treatment of attention deficit hyperactivity disorder without the potential drug abuse liability associated with current psychostimulant therapies. Expand
Neurochemical arguments for the use of dopamine D4 receptor stimulation to improve cognitive impairment associated with schizophrenia
TLDR
Results indicate D4 receptor agonism alone is sufficient to increase cortical DA and ACh efflux without interfering with the effects of lurasidone and possibly other atypical APDs on extracellular corticalDA and Ach levels. Expand
Dopamine D4 receptor stimulation contributes to novel object recognition: Relevance to cognitive impairment in schizophrenia
TLDR
D4 receptor agonism has a beneficial effect on novel object recognition in sub-chronic PCP-treated rats and augments the cognitive enhancing efficacy of an atypical antipsychotic drug that lacks affinity for the D4 receptor, lurasidone. Expand
Dopamine D4 Receptor-Selective Compounds Reveal Structure–Activity Relationships that Engender Agonist Efficacy
TLDR
A series of eighteen novel ligands based on the classical D4R agonist A-412997 are reported, highlighting receptor–ligand interactions that control efficacy at D2-like receptors and may provide insights into targeted drug discovery, leading to a better understanding of the role of D4Rs in neuropsychiatric disorders. Expand
WAY-100635 has high selectivity for serotonin 5-HT(1A) versus dopamine D(4) receptors.
TLDR
Data demonstrate that WAY-100635 has high selectivity for serotonin h5-HT(1A)versus dopamine hD(4.4) receptors. Expand
Lack of dopamine D4 receptor participation in mouse hyperdopaminergic locomotor response
TLDR
The results suggest the mesolimbic D4R does not participate in behavioral sensitization encoded by hyperdopaminergia, a finding which likely extends to the therapeutic effects of Clz. Expand
Behavioral and neurophysiological effects of Ro 10-5824, a dopamine D4 receptor partial agonist, in common marmosets
TLDR
Activation of D4R by Ro 10-5824 improves the success rate in the ORD task and increases baseline gamma band activity in the frontal cortex without affecting locomotion in common marmosets, highlighting the role of D 4R in gamma oscillations of non-human primates. Expand
The effect of reduced dopamine D4 receptor expression in the 5-choice continuous performance task: Separating response inhibition from premature responding
TLDR
Reduced Drd4 expression in HT mice impairs attentional performance, but not other behaviors associated with neuropsychiatric disorders, and the use of signal and non-signal stimuli in the 5C-CPT enabled the differentiation of response disinhibition from motor impulsivity in a vigilance task. Expand
PD168077, a D4 receptor agonist, reverses object recognition deficits in rats: potential role for D4 receptor mechanisms in improving cognitive dysfunction in schizophrenia
TLDR
The results suggest that D4 receptor activation can improve cognitive dysfunction in an animal model relevant to schizophrenia. Expand
Enhancement of gamma activity after selective activation of dopamine D4 receptors in freely moving rats and in a neurodevelopmental model of schizophrenia
TLDR
The involvement of D4R in cortical gamma oscillations in vivo is demonstrated and this receptor is identified as potential target for pharmacological treatment of cognitive deficits. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 34 REFERENCES
A-412997 is a selective dopamine D4 receptor agonist in rats
TLDR
Dopamine D4 receptor selective agonists have been shown to induce penile erection in rats by central mechanisms and a useful tool to understand the role of dopamine D4 receptors in rat models of central nervous system processes and disease. Expand
RO-10-5824 is a selective dopamine D4 receptor agonist that increases novel object exploration in C57 mice
TLDR
The hypothesis that stimulation of D4R can enhance novelty seeking in mice and that this effect may be dependent on subtle genetic differences is supported. Expand
Effects of dopamine D4 receptor-selective antagonists on motor hyperactivity in rats with neonatal 6-hydroxydopamine lesions
TLDR
Motor hyperactivity in this ADHD model was selectively antagonized by three of four dopamine D4 receptor antagonists evaluated, encouraging clinical assessment of D4 antagonists in patients with ADHD. Expand
Facilitatory effect of the dopamine D4 receptor agonist PD168,077 on memory consolidation of an inhibitory avoidance learned response in C57BL/6J mice
TLDR
A potential role of dopamine D4 receptors in memory consolidation is suggested, which would be similar to the D1 and D2 receptors and probably opposite to that of the D3 receptors. Expand
The effects of a selective D4 dopamine receptor antagonist (L-745,870) in acutely psychotic inpatients with schizophrenia. D4 Dopamine Antagonist Group.
TLDR
The selective D4 dopamine receptor antagonist L-745,870 was ineffective as an antipsychotic for the treatment of neuroleptic responsive inpatients with acute schizophrenia. Expand
The novel dopamine D4 receptor agonist (PD 168,077 maleate): Doses with different effects on locomotor activity are without effect in classical conditioning
TLDR
No evidence is found that the D( 4) receptor has any likely effect on associative learning or its disorder, and D(4)-mediated hyperactivity was dissociable from cognitive effects. Expand
Role of Dopamine D4 Receptors in Motor Hyperactivity Induced by Neonatal 6-Hydroxydopamine Lesions in Rats
TLDR
Autoradiographic analysis indicated that motor hyperactivity in lesioned rats was closely correlated with increases in D4 but not D2 receptor levels in caudate-putamen, and may suggest much-needed innovative treatments for ADHD. Expand
The dopamine D4 receptor is essential for hyperactivity and impaired behavioral inhibition in a mouse model of attention deficit/hyperactivity disorder
TLDR
Results from a combination of genetic and pharmacological approaches demonstrate that D4R signaling is essential for the expression of juvenile hyperactivity and impaired behavioral inhibition, relevant features present in this ADHD-like mouse model. Expand
Effects of histamine H3 receptor ligands GT-2331 and ciproxifan in a repeated acquisition avoidance response in the spontaneously hypertensive rat pup
TLDR
A repeated acquisition version of an inhibitory avoidance task using spontaneously hypertensive rat (SHR) pups is developed that is believed to provide a reproducible measure of the cognitive and attention deficits often characteristic of these disease states, and two H(3) receptor antagonists are evaluated. Expand
Two Novel and Selective Nonimidazole H3 Receptor Antagonists A-304121 and A-317920: II. In Vivo Behavioral and Neurophysiological Characterization
  • G. Fox, J. Pan, +9 authors A. Hancock
  • Chemistry, Medicine
  • Journal of Pharmacology and Experimental Therapeutics
  • 2003
TLDR
A-304121 and A-317920 represent a series of novel, H3R-selective piperazine amides that enhance cognition in vivo, which could offer advantages over existing H3 R antagonists or cognition-enhancing agents. Expand
...
1
2
3
4
...